Pharmaceutical Group: Bayer plans to cut 12,000 jobs in the world



[ad_1]

economy The pharmaceutical group

Bayer plans to cut 12,000 jobs worldwide

| Reading time: 2 minutes

Nearly 100,000 people work at Bayer worldwide Nearly 100,000 people work at Bayer worldwide

Nearly 100,000 people work at Bayer worldwide

Source: REUTERS

A "significant part" should be omitted in Germany, said Bayer. Society is fighting on many fronts. In the United States, the group faces numerous lawsuits.

rePharmaceutical and agrochemical group Bayer Leverkusen, Bayer, plans to cut 12,000 jobs worldwide by the end of 2021, many of them in Germany. Most of the job cuts will be attributable to Crop Protection and all of the company's functions, the company said in Leverkusen on Thursday.

At the same time, Bayer agreed with the company committee in Germany a program for the future, which will exclude layoffs on Bayer AG staff in Germany until the end of 2025. The reduction of jobs in Germany should be "socially acceptable", says the press release. The details would be settled in the coming months. According to its own information, the group employs 118,200 people worldwide.

The structural and efficiency measures aim to increase the competitiveness of the Dax Group and generate an annual contribution of € 2.6 billion, including the synergies expected from the Monsanto acquisition in 2022.

Bayer is currently fighting on several fronts

The reduction of the workforce is part of an efficiency improvement program designed to significantly increase productivity and profitability. Other items include the sale of the animal health business, the sale of Coppertone and Drs. Scholl's and the sale of the 60% stake in the German site chemical service provider Currenta.

Bayer is currently fighting on several fronts. In the United States, following the Monsanto acquisition, the group faces numerous claims for glyphosate herbicide. The plaintiffs accuse Monsanto's American company, acquired by Bayer, of selling a carcinogen containing glyphosate and of not being sufficiently informed of the harmfulness. Bayer resolutely rejects these allegations. But Bayer's action has collapsed after the first glyphosate loss process mbadively. In the pharmaceutical sector, too, the group had recently announced few promising new developments.

[ad_2]
Source link